Close Menu

cervical cancer

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Qiagen and Roche today welcomed new guidelines recommending the use of molecular testing for human papillomavirus screening in conjunction with Pap smears.

This story has been updated from a previous version to clarify comments regarding the Aptima HPV test specificity.
By Ben Butkus

The device, named the Verisante Aura, uses Raman spectroscopy to measure levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions. In initial clinical trials it distinguished between benign and malignant lesions with 100-percent sensitivity and 70-percent specificity.

The assay may provide insight into the relationships between various HPV types and their associated diseases — not just cervical cancer, but also potentially head and neck cancers and HPV-associated warts.

Roche presents data from HPV Dx trial; Epigenomics launches Epi proLung BL Reflex Assay in Europe.

Incell's HPV test will be run on Accuri's cytometer as a cervical cancer screening tool.

Enzo Clinical Labs will market the cervical cancer test in New York and New Jersey.

Using gene dosage, expression, and ontology data, the researchers identified recurrent changes linked to cervical cancer development and treatment outcomes.

After comparing results from Qiagen's HPV DNA test with cytology-based screening in more than 100,000 women, the researchers concluded that the HPV test is more sensitive, though its specificity varied by age group.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.